Novel pyrimidine-based CXCR2 chemokine receptor antagonists

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 10, 2004, Pages 1507-1510

[No Author Info available]

Author keywords

Chronic obstructive pulmonary disease (COPD); CXCR2 chemokine receptor; Growth related oncogene (GRO ); IL 8; Inflammation; Neutrophil

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; 6 AMINO 2 BENZYLTHIO 4 HYDROXYPYRIMIDINE DERIVATIVE; AZD 8309; CHEMOKINE RECEPTOR CXCR2; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RECEPTOR BLOCKING AGENT; RESPIRATORY TRACT AGENT; SB 332235; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ARTICLE; ASTHMA; BINDING AFFINITY; CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENTERITIS; HUMAN; OSTEOARTHRITIS; PHYSICAL CHEMISTRY; PSORIASIS; RHEUMATOID ARTHRITIS;

EID: 5744249662     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.10.1507     Document Type: Article

References (8)

1. EHLERT JE: Chemokines and chemokine receptors: disease targets for therapeutic development. Expert Opin. Investig. Drugs (2000) 9:627-629.
2. ONUFFER JJ, HORUK R: Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol. Sci. (2002) 23:459-467.
3. NORMAN P: Developing anti-inflammatory drugs for the treatment of COPD. Inflamm. Res. in press.
4. JIE JL: Small molecule interleukin-8 modulators. Expert Opin. Ther. Patents (2001) 11:1905-1910.
5. TRAVES SL, SMITH SJ, BARNES PJ, DONNELLY LE: Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J. Leukoc. Biol. in press.
6. WHITE JR, LEE JM, YOUNG PR et al.: Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem. (1998) 273:10095-10098.
7. WIDDOWSON KL, ELLIOTT JD, VEBER DF et al.: Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J. Med. Chem. (2004) 47:1319-1321.
8. BAXTER A, BENNION C, BENT J et al.: Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13 2625-2628.